The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer ...

We also explain how quickly they work, how long they last and why supplements and other over-the-counter options ... to a class of medications called PDE5 inhibitors, short for phosphodiesterase ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Just over a month after getting FDA approval for ... At the moment, ED is mainly treated with oral PDE5 inhibitors, like Pfizer’s Viagra (sildenafil) and Eli Lilly’s Cialis (tadalafil ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

Opella reaches study milestone for CialisParis, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and ...

French pharma major Sanofi’s consumer healthcare business, Opella, has announced that the US Food and Drug Administration ...

Furthermore, continuation rates were over 80 % regardless of the presence of comorbidities, pretreatment with PDE5 inhibitors, or ED severity. Even in the subgroup of older patients (>65 years ...

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis ...